MXPA05010160A - Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias. - Google Patents

Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.

Info

Publication number
MXPA05010160A
MXPA05010160A MXPA05010160A MXPA05010160A MXPA05010160A MX PA05010160 A MXPA05010160 A MX PA05010160A MX PA05010160 A MXPA05010160 A MX PA05010160A MX PA05010160 A MXPA05010160 A MX PA05010160A MX PA05010160 A MXPA05010160 A MX PA05010160A
Authority
MX
Mexico
Prior art keywords
oxitropium
roflumilast
ipratropium
treatment
agent selected
Prior art date
Application number
MXPA05010160A
Other languages
English (en)
Inventor
Wollin Stefan-Lutz
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of MXPA05010160A publication Critical patent/MXPA05010160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a la administracion de roflumilast oral o intravenosamente y un agente anticolinergico seleccionado a partir del grupo de sal de ipatropio, oxitropio o tiotropio para el tratamiento de enfermedades respiratorias.
MXPA05010160A 2003-03-28 2004-03-26 Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias. MXPA05010160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03007104 2003-03-28
PCT/EP2004/050376 WO2004084896A1 (en) 2003-03-28 2004-03-26 Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
MXPA05010160A true MXPA05010160A (es) 2005-11-16

Family

ID=33040925

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010160A MXPA05010160A (es) 2003-03-28 2004-03-26 Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.

Country Status (13)

Country Link
US (1) US20060147382A1 (es)
EP (1) EP1610787B1 (es)
AT (1) ATE384529T1 (es)
CA (1) CA2519679C (es)
CY (1) CY1110373T1 (es)
DE (1) DE602004011494T2 (es)
DK (1) DK1610787T3 (es)
ES (1) ES2300755T3 (es)
MX (1) MXPA05010160A (es)
PL (1) PL1610787T3 (es)
PT (1) PT1610787E (es)
SI (1) SI1610787T1 (es)
WO (1) WO2004084896A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
PT1713471E (pt) * 2004-02-06 2012-04-10 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e inibidores de fosfodiesterase tipo 4 para o tratamento de doenças respiratórias
SI1713473T1 (sl) * 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
ES2317245T3 (es) * 2004-05-31 2009-04-16 Laboratorios Almirall, S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US20060219242A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Method for the Administration of an Anticholinergic by Inhalation
CA2623882A1 (en) * 2005-09-28 2007-04-05 Merck Frosst Canada Ltd. Aerosol powder formulation comprising sieved lactose
NZ591969A (en) 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE283033T1 (de) * 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
DE10110772A1 (de) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
IL158776A0 (en) * 2001-05-25 2004-05-12 Pfizer A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
AU2002314102A1 (en) * 2001-05-25 2002-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases

Also Published As

Publication number Publication date
CY1110373T1 (el) 2015-04-29
CA2519679A1 (en) 2004-10-07
US20060147382A1 (en) 2006-07-06
DK1610787T3 (da) 2008-06-02
PT1610787E (pt) 2008-04-23
CA2519679C (en) 2012-08-28
WO2004084896A1 (en) 2004-10-07
EP1610787B1 (en) 2008-01-23
SI1610787T1 (sl) 2008-06-30
DE602004011494D1 (de) 2008-03-13
EP1610787A1 (en) 2006-01-04
ES2300755T3 (es) 2008-06-16
PL1610787T3 (pl) 2008-07-31
ATE384529T1 (de) 2008-02-15
DE602004011494T2 (de) 2009-01-22

Similar Documents

Publication Publication Date Title
CY1110373T1 (el) Συνεργιστικος συνδυασμος που περιλαμβανει ροφλουμιλαστη και εναν αντιχολινεργικο παραγοντα που επιλεγεται απο αλατα τιοτροπιου για την θεραπεια αναπνευστικων ασθενειων
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
MXPA05010161A (es) Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
WO2008004100A9 (en) Therapeutic compounds
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
WO2007104933A8 (en) Chemical compounds
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
MX2008013477A (es) Compuestos biciclicos de tetrahidropirrol.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status
HC Change of company name or juridical status